Valdebenito-Navarrete Héctor, Fuentes-Barrera Victor, Smith Carlos T, Salas-Burgos Alexis, Zuniga Felipe A, Gomez Leonardo A, García-Cancino Apolinaria
Laboratory of Bacterial Pathogenicity, Department of Microbiology, Faculty of Biological Sciences, Universidad de Concepción, Concepción 4070386, Chile.
Department of Microbiology, Faculty of Biological Sciences, Universidad de Concepción, Concepción 4070386, Chile.
Biology (Basel). 2023 Feb 28;12(3):384. doi: 10.3390/biology12030384.
COVID-19, an infection produced by the SARS-CoV-2 virus in humans, has rapidly spread to become a high-mortality pandemic. SARS-CoV-2 is a single-stranded RNA virus characterized by infecting epithelial cells of the intestine and lungs, binding to the ACE2 receptor present on epithelial cells. COVID-19 treatment is based on antivirals and antibiotics against symptomatology in addition to a successful preventive strategy based on vaccination. At this point, several variants of the virus have emerged, altering the effectiveness of treatments and thereby attracting attention to several alternative therapies, including immunobiotics, to cope with the problem. This review, based on articles, patents, and an in silico analysis, aims to address our present knowledge of the COVID-19 disease, its symptomatology, and the possible beneficial effects for patients if probiotics with the characteristics of immunobiotics are used to confront this disease. Moreover, two probiotic strains, UCO-979C and UCO-25A, with different effects demonstrated at our laboratory, are emphasized. The point of view of this review highlights the possible benefits of probiotics, particularly those associated with immunomodulation as well as the production of secondary metabolites, and their potential targets during SARS-CoV-2 infection.
新型冠状病毒肺炎（COVID-19）是由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染人类所引发的疾病，已迅速传播成为一种高致死率的大流行病。SARS-CoV-2是一种单链RNA病毒，其特征在于感染肠道和肺部的上皮细胞，并与上皮细胞上存在的血管紧张素转换酶2（ACE2）受体结合。COVID-19的治疗基于针对症状的抗病毒药物和抗生素，此外还有基于疫苗接种的成功预防策略。此时，该病毒已出现多种变体，改变了治疗效果，从而引发了对包括免疫生物制剂在内的几种替代疗法的关注，以应对这一问题。本综述基于文章、专利和计算机模拟分析，旨在阐述我们目前对COVID-19疾病及其症状学的认识，以及如果使用具有免疫生物制剂特性的益生菌来对抗该疾病，对患者可能产生的有益影响。此外，还重点介绍了在我们实验室表现出不同效果的两种益生菌菌株，即UCO-979C和UCO-25A。本综述的观点强调了益生菌的潜在益处，特别是那些与免疫调节以及次级代谢产物产生相关的益处，以及它们在SARS-CoV-2感染期间的潜在作用靶点。
